India

ADD (previously HOLD)

Consensus ratings*: Buy 8	Hold 3	Sell 7
Current price:		Rs1,130
Target price:		Rs1,268
Previous target:		Rs1,268
Up/downside:		12.2%
InCred Research / Consensus:		3.8%
Reuters:		IPCA.NS
Bloomberg:		IPCA IN
Market cap:	US	\$3,436m
	Rs2	86,557m
Average daily turnover:	ι	JS\$7.8m
	R	s652.2m
Current shares o/s:		253.7m
Free float: *Source: Bloomberg		53.7%

Key changes in this note

 Upgrade our rating on the stock to ADD from HOLD earlier.



Ipca Laboratories Ltd

Pharmaceuticals | India | July 01, 2024

Price correction gives favourable entry point

- Unichem arm posted strong FY24 results. Healthy FY25F performance is also likely from it, with a 20% revenue growth & 500-600bp margin improvement.
- Ipca Labs may post a healthy growth of 11-11.5%. Margin growth to continue with a 100-130bp rise on a standalone basis & ~150bp rise on a consol. basis.
- Recent price correction offers a favourable risk-reward ratio and a good entry point. Upgrade our rating to ADD with an unchanged target price of Rs1,268.

Unichem subsidiary is gradually moving on the right track

Unichem ended FY24 on a strong note (posting an EBITDA of Rs1bn as against a loss of Rs450m in FY23 and turning profitable) and is geared to post a strong FY25F performance as well. Ipca Laboratories expects Unichem to clock around Rs20bn in revenue (20% YoY growth) and around Rs2.25bn EBITDA in FY25F, implying around 10-11% margin (an improvement of 500-600bp YoY). Beyond FY25F, Ipca Laboratories expects Unichem's margin to touch 15%.

Decent guidance indicates consistent growth likely ahead

Ipca Laboratories expects its India business and export generics business to grow 12% YoY in FY25F, although the branded business is likely to show a moderate performance due to depreciation of the Russian rouble as well as problems in West Africa. The institutional business is expected to grow at 14% YoY while the API business should grow by 7-8% YoY – all these combined should drive an 11–11.5% growth overall for Ipca Laboratories (ex-Unichem). The US business should see around six-to-seven product launches during the year, although a meaningful swing should show up only from FY26F. The standalone margin is likely to be around 20.5-21% (an improvement of 100-130bp), although, including Unichem, the consolidated business should post around 18% (an improvement of ~150bp). Scale-up of the US business should aid the momentum in margins.

Upgrade our rating on the stock to ADD from HOLD

With plant compliance issues largely behind and Unichem delivering on expected synergies, we believe lpca Laboratories' growth trajectory should materially improve over the next two years. Further, with the recent price correction, the valuation has become reasonable, and the risk-reward ratio offers a favourable entry point. We upgrade our rating on the stock to ADD (from HOLD earlier) with unchanged target price of Rs1,268. Slower margin expansion in Unichem is a downside risk.

Research Analyst(s)




Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 8850099267 E yogesh.soni@incredresearch.com

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	58,298	62,443	77,074	87,681	99,661
Operating EBITDA (Rsm)	13,093	9,268	12,821	16,017	20,696
Net Profit (Rsm)	8,841	4,713	5,474	7,897	10,727
Core EPS (Rs)	34.8	18.6	23.3	31.1	42.3
Core EPS Growth	(22.5%)	(46.7%)	25.3%	33.7%	35.8%
FD Core P/E (x)	32.42	60.81	48.53	36.29	26.72
DPS (Rs)	8.0	4.0	4.0	5.0	5.0
Dividend Yield	0.71%	0.35%	0.35%	0.44%	0.44%
EV/EBITDA (x)	21.31	29.90	23.61	18.87	14.47
P/FCFE (x)	29.25	26.12	(355.42)	33.90	20.21
Net Gearing	(10.1%)	(12.2%)	6.8%	5.0%	0.7%
P/BV (x)	5.22	4.91	4.53	4.11	3.66
ROE	17.3%	8.3%	9.7%	11.9%	14.5%
% Change In Core EPS Estimates					
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS



Profit & Loss

Pharmaceuticals | India

Ipca Laboratories Ltd | July 01, 2024

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	58,298	62,443	77,074	87,681	99,661
Gross Profit	38,149	39,378	51,317	58,747	67,271
Operating EBITDA	13,093	9,268	12,821	16,017	20,696
Depreciation And Amortisation	(2,324)	(2,616)	(3,572)	(4,000)	(4,500)
Operating EBIT	10,768	6,652	9,249	12,017	16,196
Financial Income/(Expense)	(77)	(455)	(1,383)	(1,300)	(1,300)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	666	1,256	1,248	1,350	1,500
Profit Before Tax (pre-El)	11,357	7,453	9,114	12,067	16,396
Exceptional Items			(687)		
Pre-tax Profit	11,357	7,453	8,427	12,067	16,396
Taxation	(2,248)	(2,534)	(3,134)	(3,620)	(4,919)
Exceptional Income - post-tax					
Profit After Tax	9,109	4,919	5,292	8,447	11,477
Minority Interests	(269)	(206)	181	(550)	(750)
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	8,841	4,713	5,474	7,897	10,727
Recurring Net Profit	8,841	4,713	5,905	7,897	10,727
Fully Diluted Recurring Net Profit	8,841	4,713	5,905	7,897	10,727

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	13,093	9,268	12,821	16,017	20,696
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(2,728)	490	(916)	(5,369)	(5,438)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(1,805)	(1,700)	(2,459)	(4,170)	(5,669)
Net Interest (Paid)/Received	(77)	(455)	(1,383)	(1,300)	(1,300)
Tax Paid	(2,394)	(2,500)	(1,637)	(4,220)	(5,869)
Cashflow From Operations	8,560	8,058	9,447	6,478	9,589
Сарех	(4,761)	(4,583)	(4,020)	(4,500)	(5,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments	(2,310)	(453)	(15,680)		
Other Investing Cashflow	(250)	(106)			
Cash Flow From Investing	1,239	2,916	(10,253)	1,978	4,589
Debt Raised/(repaid)					
Proceeds From Issue Of Shares					
Shares Repurchased					
Dividends Paid	(1,015)	(1,015)	(507)	(1,015)	(1,269)
Preferred Dividends					
Other Financing Cashflow	9,828	6,194	1,763	11,421	(1,643)
Cash Flow From Financing	8,813	5,179	1,256	10,406	(2,911)
Total Cash Generated	10,052	8,095	(8,997)	12,384	1,678
Free Cashflow To Equity	9,800	10,974	(806)	8,456	14,178
Free Cashflow To Firm	9,877	11,429	576	9,756	15,478

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Pharmaceuticals | India Ipca Laboratories Ltd | July 01, 2024

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	13,703	21,798	8,646	21,030	22,708
Total Debtors	9,108	9,890	16,865	18,413	20,929
Inventories	18,580	17,434	24,696	26,304	29,898
Total Other Current Assets	3,181	2,771	5,182	6,138	6,976
Total Current Assets	44,572	51,893	55,389	71,885	80,511
Fixed Assets	25,152	26,946	46,631	47,131	47,631
Total Investments	2,699	3,027	3,036	3,036	3,036
Intangible Assets	2,088	1,972	2,333	2,333	2,333
Total Other Non-Current Assets	1,879	2,427	3,624	3,624	3,624
Total Non-current Assets	31,817	34,372	55,624	56,124	56,624
Short-term Debt	4,005	8,058	8,071	8,071	8,071
Current Portion of Long-Term Debt					
Total Creditors	8,595	5,251	7,761	7,905	8,744
Other Current Liabilities	2,058	4,750	7,725	6,324	6,995
Total Current Liabilities	14,659	18,058	23,556	22,300	23,811
Total Long-term Debt	4,067	6,518	5,804	17,175	15,332
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	1,974	2,535	4,382	4,382	4,382
Total Non-current Liabilities	6,041	9,053	10,186	21,557	19,714
Total Provisions					
Total Liabilities	20,700	27,111	33,743	43,857	43,525
Shareholders Equity	54,920	58,420	63,322	69,654	78,362
Minority Interests	769	733	13,948	14,498	15,248
Total Equity	55,689	59,153	77,270	84,152	93,610
Key Ratios	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue Growth	7.6%	7.1%	23.4%	13.8%	13.7%
Operating EBITDA Growth	(15.2%)	(29.2%)	38.3%	24.9%	29.2%
Operating EBITDA Margin	22.5%	14.8%	16.6%	18.3%	20.8%
Net Cash Per Share (Rs)	22.19	28.47	(20.61)	(16.62)	(2.74)
BVPS (Rs)	216.47	230.27	249.59	274.55	308.87
BVPS (Rs) Gross Interest Cover	216.47 140.03	230.27 14.61	249.59 6.69	274.55 9.24	
					308.87 12.46 30.0%
Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	140.03	14.61	6.69	9.24	12.46
Gross Interest Cover Effective Tax Rate	140.03	14.61	6.69	9.24	12.46 30.0%
Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	140.03 19.8%	14.61 34.0%	6.69 37.2%	9.24 30.0%	12.46 30.0% 72.04
Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	140.03 19.8% 53.92	14.61 34.0% 55.52	6.69 37.2% 63.35	9.24 30.0% 73.43	12.46 30.0% 72.04 316.67
Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	140.03 19.8% 53.92 312.74	14.61 34.0% 55.52 284.95	6.69 37.2% 63.35 298.50	9.24 30.0% 73.43 321.67	12.46 30.0% 72.04 316.67 93.81
Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	140.03 19.8% 53.92 312.74 138.19	14.61 34.0% 55.52 284.95 109.55	6.69 37.2% 63.35 298.50 92.19	9.24 30.0% 73.43 321.67 98.81	12.46

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Pharmaceuticals | India Ipca Laboratories Ltd | July 01, 2024

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from he subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.